therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-8156РостГМУ10.21886/2712-8156-2022-3-2-32-40therapeutic-231Research ArticleОБЗОРЫREVIEWSИнгибиторы PCSK9: роль в снижении сердечно-сосудистой заболеваемостиPCSK9 inhibitors: role in reducing cardiovascular diseaseshttps://orcid.org/0000-0003-1522-1466МаляревскаяО. В.MalyarevskayaO. V.

Ольга Владимировна Маляревская, кардиолог кардиологического отделения № 1

SPIN-код 1213-0046

Краснодар

Olga V. Malyarevskaya, cardiologist of the Department of Emergency Cardiology № 1

Krasnodar

olga.malyarevskaya@mail.ruhttps://orcid.org/0000-0002-5866-506XНамитоковА. М.NamitokovA. M.

Алим Муратович Намитоков, к. м. н., заведующий отделением экстренной кардиологии № 2

Краснодар

Alim M. Namitokov, PhD, Head of the Department of Emergency Cardiology № 2

Krasnodar

https://orcid.org/0000-0002-7538-0437КручиноваС. В.KruchinovaS. V.

София Владимировна Кручинова, кардиолог кардиологического отделения № 1

Краснодар

Sofia V. Kruchinova, cardiologist of the Department of Emergency Cardiology № 1

Krasnodar

https://orcid.org/0000-0001-8600-0199КосмачеваЕ. Д.KosmachevaE. D.

Елена Дмитриевна Космачева, д. м. н., проф., заместитель главного врача по медицинской части

Краснодар

Elena D. Kosmacheva, M.D, Deputy Chief Physician for Medical Care

Krasnodar

ГБУЗ «Научно-исследовательский институт – Краевая клиническая больница № 1 им. С. В. Очаповского»РоссияS. V. Ochapovsky Scientific institution – Regional Clinical Hospital № 1Russian Federation202219062022323240Copyright © Маляревская О.В., Намитоков А.М., Кручинова С.В., Космачева Е.Д., 20222022Маляревская О.В., Намитоков А.М., Кручинова С.В., Космачева Е.Д.Malyarevskaya O.V., Namitokov A.M., Kruchinova S.V., Kosmacheva E.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/231

В данном обзоре будет представлен разбор механизмов влияния PCSK9 на липидный обмен и его роль в развитии сердечно-сосудистой патологии, оценка эффективности и безопасности ингибиторов PCSK9, место ингибиторов PCSK9 в клинических рекомендациях Европейского, Российского кардиологического общества и Американской коллегии сердца.

This review will present an analysis of the mechanisms of PCSK9 influence on lipid metabolism and its role in the development of cardiovascular pathology, an assessment of the effectiveness and safety of PCSK9 inhibitors, the place of PCSK9 inhibitors in the clinical recommendations of the European, Russian Cardiological Society and the American College of the Heart.

PCSK9эволокумабалирокумабрецептор-ЛПНПлипопротеин(a)PCSK9evolocumabalirocumabLDL receptorlipoprotein(a)ReferencesYusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. DOI: 10.1016/S0140-6736(04)17018-9.Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. DOI: 10.1016/S0140-6736(04)17018-9.Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract. 2016;2016(4):e201635. DOI: 10.21542/gcsp.2016.35.Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract. 2016;2016(4):e201635. DOI: 10.21542/gcsp.2016.35.Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80. DOI: 10.1001/jama.291.9.1071.Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80. DOI: 10.1001/jama.291.9.1071.Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009;54(24):2290-5. DOI: 10.1016/j.jacc.2009.09.010.Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009;54(24):2290-5. DOI: 10.1016/j.jacc.2009.09.010.LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. DOI: 10.1056/NEJMoa050461.LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. DOI: 10.1056/NEJMoa050461.Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. DOI: 10.2217/clp.10.84.Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. DOI: 10.2217/clp.10.84.Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645-654; discussion 653-4. DOI: 10.1016/j.jvs.2006.12.054.Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645-654; discussion 653-4. DOI: 10.1016/j.jvs.2006.12.054.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9. PMID: 7968073.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9. PMID: 7968073.Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A-41A. DOI: 10.1016/j.amjcard.2005.11.014.Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A-41A. DOI: 10.1016/j.amjcard.2005.11.014.Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022-36. DOI: 10.1161/CIRCRESAHA.114.301621.Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022-36. DOI: 10.1161/CIRCRESAHA.114.301621.Sundararaman SS, Döring Y, van der Vorst EPC. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines. 2021;9(7):793. DOI: 10.3390/biomedicines9070793.Sundararaman SS, Döring Y, van der Vorst EPC. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines. 2021;9(7):793. DOI: 10.3390/biomedicines9070793.Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/ kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G805-15. DOI: 10.1152/ajpgi.90424.2008.Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/ kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G805-15. DOI: 10.1152/ajpgi.90424.2008.Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009;390(4):1288-93. DOI: 10.1016/j.bbrc.2009.10.138.Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009;390(4):1288-93. DOI: 10.1016/j.bbrc.2009.10.138.Ferri N, Ruscica M, Coggi D, Bonomi A, Amato M, Frigerio B, et al. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis. 2020;309:39-46. DOI: 10.1016/j.atherosclerosis.2020.07.014.Ferri N, Ruscica M, Coggi D, Bonomi A, Amato M, Frigerio B, et al. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis. 2020;309:39-46. DOI: 10.1016/j.atherosclerosis.2020.07.014.Kim EJ, Wierzbicki AS. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Ther Adv Chronic Dis. 2020;11:2040622320924569. DOI: 10.1177/2040622320924569.Kim EJ, Wierzbicki AS. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Ther Adv Chronic Dis. 2020;11:2040622320924569. DOI: 10.1177/2040622320924569.Бенимецкая К.С., Ячменева М.П., Астраков С.В., Щербакова Л.В., Денисова Д.В., Рагино Ю.И., и др. Связь пропротеин конвертазы субтилизин/кексин 9 типа (PCSK9) с уровнем артериального давления и статусом курения. Инновационная медицина Кубани. 2019;(1):20-27. eLIBRARY ID: 39220180Бенимецкая К.С., Ячменева М.П., Астраков С.В., Щербакова Л.В., Денисова Д.В., Рагино Ю.И., и др. Связь пропротеин конвертазы субтилизин/кексин 9 типа (PCSK9) с уровнем артериального давления и статусом курения. Инновационная медицина Кубани. 2019;(1):20-27. eLIBRARY ID: 39220180Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50 Suppl(Suppl):S172-7. DOI: 10.1194/jlr.R800091-JLR200.Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50 Suppl(Suppl):S172-7. DOI: 10.1194/jlr.R800091-JLR200.Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res. 2018;122(10):1420-1438. DOI: 10.1161/CIRCRESAHA.118.311227.Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res. 2018;122(10):1420-1438. DOI: 10.1161/CIRCRESAHA.118.311227.Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 2002;298(5602):2353-8. DOI: 10.1126/science.1078124.Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 2002;298(5602):2353-8. DOI: 10.1126/science.1078124.Wiciński M, Żak J, Malinowski B, Popek G, Grześk G. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017;8(4):391-402. DOI: 10.1007/s13167-017-0106-6.Wiciński M, Żak J, Malinowski B, Popek G, Grześk G. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017;8(4):391-402. DOI: 10.1007/s13167-017-0106-6.Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012;287(52):43492-501. DOI: 10.1074/jbc.M112.394023.Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012;287(52):43492-501. DOI: 10.1074/jbc.M112.394023.Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018;57(7):769-779. DOI: 10.1007/s40262-017-0620-7.Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018;57(7):769-779. DOI: 10.1007/s40262-017-0620-7.Mousavi SA, Berge KE, Berg T, Leren TP. Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells. FEBS J. 2011;278(16):2938-50. DOI: 10.1111/j.1742-4658.2011.08219.x.Mousavi SA, Berge KE, Berg T, Leren TP. Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells. FEBS J. 2011;278(16):2938-50. DOI: 10.1111/j.1742-4658.2011.08219.x.Strøm TB, Tveten K, Leren TP. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum. Biochem J. 2014;457(1):99-105. DOI: 10.1042/BJ20130930.Strøm TB, Tveten K, Leren TP. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum. Biochem J. 2014;457(1):99-105. DOI: 10.1042/BJ20130930.Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71-7. DOI: 10.1016/j.tibs.2006.12.008.Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71-7. DOI: 10.1016/j.tibs.2006.12.008.Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res. 2009;50 Suppl(Suppl):S15-27. DOI: 10.1194/jlr.R800054-JLR200.Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res. 2009;50 Suppl(Suppl):S15-27. DOI: 10.1194/jlr.R800054-JLR200.Poirier S, Hamouda HA, Villeneuve L, Demers A, Mayer G. Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. PLoS One. 2016;11(6):e0157230. DOI: 10.1371/journal.pone.0157230.Poirier S, Hamouda HA, Villeneuve L, Demers A, Mayer G. Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. PLoS One. 2016;11(6):e0157230. DOI: 10.1371/journal.pone.0157230.Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-offunction mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514-23. DOI: 10.1086/507488.Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-offunction mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514-23. DOI: 10.1086/507488.Bernards R. Exploring the uses of RNAi--gene knockdown and the Nobel Prize. N Engl J Med. 2006;355(23):2391-3. DOI: 10.1056/NEJMp068242.Bernards R. Exploring the uses of RNAi--gene knockdown and the Nobel Prize. N Engl J Med. 2006;355(23):2391-3. DOI: 10.1056/NEJMp068242.Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106(24):9820-5. DOI: 10.1073/pnas.0903849106.Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106(24):9820-5. DOI: 10.1073/pnas.0903849106.Ito MK, Santos RD. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7-32. DOI: 10.1002/jcph.766.Ito MK, Santos RD. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7-32. DOI: 10.1002/jcph.766.Lepor NE, Kereiakes DJ. The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice. Am Health Drug Benefits. 2015;8(9):483-9. PMID: 26834934; PMCID: PMC4719137.Lepor NE, Kereiakes DJ. The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice. Am Health Drug Benefits. 2015;8(9):483-9. PMID: 26834934; PMCID: PMC4719137.Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017;2(6):598-607. DOI: 10.1001/jamacardio.2017.0747.Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017;2(6):598-607. DOI: 10.1001/jamacardio.2017.0747.Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82. DOI: 10.1001/jama.2014.4030.Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82. DOI: 10.1001/jama.2014.4030.Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-2548. DOI: 10.1016/j.jacc.2014.03.019.Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-2548. DOI: 10.1016/j.jacc.2014.03.019.Hassan M, Yacoub M. GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. Glob Cardiol Sci Pract. 2014;2014(4):360-6. DOI: 10.5339/gcsp.2014.49.Hassan M, Yacoub M. GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. Glob Cardiol Sci Pract. 2014;2014(4):360-6. DOI: 10.5339/gcsp.2014.49.Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132-2146. DOI: 10.1016/j.jacc.2019.08.1024.Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132-2146. DOI: 10.1016/j.jacc.2019.08.1024.Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. DOI: 10.1001/jama.2016.16951.Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. DOI: 10.1001/jama.2016.16951.Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962-1971. DOI: 10.1016/S0140-6736(17)32290-0.Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962-1971. DOI: 10.1016/S0140-6736(17)32290-0.Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633-643. DOI: 10.1056/NEJMoa1701131.Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633-643. DOI: 10.1056/NEJMoa1701131.European Medicines Agency Science Medicines Health. Assessment report. Praluent. 2015.European Medicines Agency Science Medicines Health. Assessment report. Praluent. 2015.Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37. DOI: 10.2217/fca.14.82.Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37. DOI: 10.2217/fca.14.82.Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-915.e13. DOI: 10.1016/j.ahj.2015.03.004.Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-915.e13. DOI: 10.1016/j.ahj.2015.03.004.Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186-94. DOI: 10.1093/eurheartj/ehv028.Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186-94. DOI: 10.1093/eurheartj/ehv028.Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. DOI: 10.1093/eurheartj/ehv370.Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. DOI: 10.1093/eurheartj/ehv370.Bhatt DL. ODYSSEY HIGH FH. American College of Cardiolody; 2014.Bhatt DL. ODYSSEY HIGH FH. American College of Cardiolody; 2014.Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, et al. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. J Clin Lipidol. 2020;14(5):707-719. DOI: 10.1016/j.jacl.2020.07.009.Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, et al. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. J Clin Lipidol. 2020;14(5):707-719. DOI: 10.1016/j.jacl.2020.07.009.Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, et al. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc. 2016;5(9):e003421. DOI: 10.1161/JAHA.116.003421.Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, et al. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc. 2016;5(9):e003421. DOI: 10.1161/JAHA.116.003421.Kastelein JP, Bavry AA, Eagle KA. ODYSSEY LONG TERM. American College of Cardiolody; 2015.Kastelein JP, Bavry AA, Eagle KA. ODYSSEY LONG TERM. American College of Cardiolody; 2015.Kumbhani DJ, Bhatt DL. ODYSSEY ALTERNATIVE: 17.11.2014. American College of Cardiolody; 2014.Kumbhani DJ, Bhatt DL. ODYSSEY ALTERNATIVE: 17.11.2014. American College of Cardiolody; 2014.Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73(4):387-396. DOI: 10.1016/j.jacc.2018.10.039.Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73(4):387-396. DOI: 10.1016/j.jacc.2018.10.039.Bavry AA, Bhatt DL. ODYSSEY ESCAPE. American College of Cardiolody; 2016.Bavry AA, Bhatt DL. ODYSSEY ESCAPE. American College of Cardiolody; 2016.Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc Diabetol. 2020;19(1):14. DOI: 10.1186/s12933-020-0991-1.Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc Diabetol. 2020;19(1):14. DOI: 10.1186/s12933-020-0991-1.Клинические рекомендации «Семейная гиперхолестеринемия». Москва; 2018.Клинические рекомендации «Семейная гиперхолестеринемия». Москва; 2018.Mach F., Baigent C., Catapano A.L., Koskinas K.С., Casula M., Badimon L., et al. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020;25(5):3826. DOI: 10.15829/1560-4071-2020-3826Mach F., Baigent C., Catapano A.L., Koskinas K.С., Casula M., Badimon L., et al. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020;25(5):3826. DOI: 10.15829/1560-4071-2020-3826Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. DOI: 10.1016/j.jacc.2018.11.002.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. DOI: 10.1016/j.jacc.2018.11.002.

The authors declare that there are no conflicts of interest present.